Chlamydia Chlamydia trachomatis
Conditions
Interventions
Sponsors
GGD Amsterdam
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: Born to female sex Age *18 years Tested Ct NAAT-positive on urogenital swab Eligible for azithromycin treatment (no allergies) Willing to receive the routine treatment for Chlamydia trachomatis at the STI Outpatient Clinic Accepting conditions of the study and signed informed consent
Exclusion criteria
Exclusion criteria: Tested NAAT-positive on urine sample only Not being able to give informed consent, based on Dutch or English patient information Ct infection in the past 3 months Antibiotic treatment for which Chlamydia trachomatis is sensitive (rifampicin, tetracyclines, macrolides, sulfonamides, quinolones, clindamycin, penicillins, cephalosporins) between day -28 and day 0. Unlikely to comply with the study requirements
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoints: Clearance of Ct infection as determined by Ct culture and NAAT at days 7, 21 and 49 after treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoint: sensitivity of Ct culture when compared to Aptima Combo 2 assay and COBAS® 4800 CT/NG TEST on the day of inclusion. To distinguish recurrent or persistent infections from new infections by determining if persistent Ct NAAT and/or culture positive results after treatment are caused by the same Ct strain. | — |
Countries
The Netherlands
Outcome results
None listed